Prolonged use of DPP-4 inhibitors in patients with type 2 diabetes raises the risk of cholecystitis by over 50% compared with placebo and non-incretin agents, a first-of-its-kind analysis shows.

This elevated risk is comparable to that seen with GLP-1 receptor agonists, which had previously been implicated in the development of impaired gallbladder motility, Chinese investigators say.